logo
Plus   Neg
Share
Email

Lanxess Plans To Start Share Buy-back Program On March 12

Specialty chemicals company Lanxess AG (LNXSF.PK) expects to start the first tranche of share buy-back on March 12, 2020 and shall be completed within the next 12 months.

In May 2019, the company was authorized to buy back up to 500 million euros via the stock exchange in the next 24 months, but not more than 10 percent of the share capital of the company.

On the basis of the current share price of 40.30 euros per share, on March 9, 2020, the company could buy back about 8.74 million own shares, or 10 percent of the share capital, for an aggregate consideration of about 352 million euros.

The company noted that it will split share buy-back into two tranches of 250 million euros each.

The company expects to start the first tranche of share buy-back on March 12, and take a decision on the second tranche of the buy-back program after completing the first tranche.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Latam Airlines Group SA, one of the largest air carrier in South America, has filed for bankruptcy protection in New York amid the ongoing Covid-19 pandemic, which has grounded flights worldwide. This Chapter 11 filing allows Latam to work with its creditors and other stakeholders to reduce its debt,... Pizza Hut said it is giving away 500,000 free pizzas to 2020 graduates in the Unites States. The pizza chain, owned by Yum! Brands, offers one free medium 1-topping pizza to all diploma/degree earning individuals until supplies last. The company is partnering with America's dairy farmers for the offer, which can be claimed until Thursday and redeemed until June 4. Merck & Co. Inc. on Tuesday announced deals, including an acquisition and two collaborations that will enable the U.S. drugmaker to join the race to develop coronavirus vaccines and drugs. Shares of Merck were rising almost 4 percent in the pre-market. Merck said it has agreed to acquire privately-held Themis, an Austria-based company focused on vaccines and immune-modulation therapies.
Follow RTT